Dusseldorf - Delayed Quote EUR
Innoviva Inc (HVE.DU)
At close: 7:30 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
330,496.00
310,463.00
331,339.00
391,866.00
336,794.00
Cost of Revenue
42,755.00
42,640.00
13,793.00
--
--
Gross Profit
287,741.00
267,823.00
317,546.00
391,866.00
336,794.00
Operating Expense
151,784.00
153,938.00
110,551.00
16,763.00
15,671.00
Operating Income
135,957.00
113,885.00
206,995.00
375,103.00
321,123.00
Net Non Operating Interest Income Expense
-5,228.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
Other Income Expense
22,269.00
83,552.00
89,374.00
87,404.00
49,929.00
Pretax Income
152,998.00
194,098.00
286,949.00
445,276.00
354,245.00
Tax Provision
7,574.00
14,376.00
66,687.00
76,439.00
60,431.00
Net Income Common Stockholders
145,424.00
179,722.00
213,921.00
265,854.00
224,402.00
Average Dilution Earnings
6,907.00
11,582.00
11,648.00
4,736.00
4,717.00
Diluted NI Available to Com Stockholders
152,331.00
191,304.00
225,569.00
270,590.00
229,119.00
Basic EPS
2.82
2.75
3.07
3.24
2.21
Diluted EPS
2.24
2.20
2.37
2.87
2.02
Basic Average Shares
64,284.75
65,435.00
69,644.00
82,062.00
101,320.00
Diluted Average Shares
85,561.75
86,876.00
95,249.00
94,311.00
113,554.00
Total Operating Income as Reported
--
--
-36,946.00
375,103.00
321,123.00
Total Expenses
194,539.00
196,578.00
124,344.00
16,763.00
15,671.00
Net Income from Continuing & Discontinued Operation
145,424.00
179,722.00
213,921.00
265,854.00
224,402.00
Normalized Income
174,428.39
169,417.28
18,569.92
260,355.52
223,766.67
Interest Income
16,773.00
15,818.00
6,369.00
1,839.00
1,524.00
Interest Expense
22,001.00
19,157.00
15,789.00
19,070.00
18,331.00
Net Interest Income
-5,228.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
EBIT
174,999.00
213,255.00
302,738.00
464,346.00
372,576.00
EBITDA
200,900.00
235,039.00
308,319.00
464,346.00
372,576.00
Reconciled Cost of Revenue
42,755.00
42,640.00
13,793.00
--
--
Reconciled Depreciation
25,901.00
21,784.00
5,581.00
--
--
Net Income from Continuing Operation Net Minority Interest
145,424.00
179,722.00
213,921.00
265,854.00
224,402.00
Total Unusual Items Excluding Goodwill
-30,515.00
11,129.00
254,496.00
6,638.00
766.00
Total Unusual Items
-30,515.00
11,129.00
254,496.00
6,638.00
766.00
Normalized EBITDA
231,415.00
223,910.00
53,823.00
457,708.00
371,810.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,510.61
824.28
59,144.92
1,139.52
130.67
12/31/2020 - 7/13/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ADXN Addex Therapeutics Ltd
11.01
+2.13%
DBVT DBV Technologies S.A.
0.7700
+0.79%
ATHA Athira Pharma, Inc.
0.7000
-6.67%
CLSD Clearside Biomedical, Inc.
1.0800
+0.93%
VIR Vir Biotechnology, Inc.
10.17
+5.50%
CUE Cue Biopharma, Inc.
1.6500
-3.51%
GMAB Genmab A/S
22.33
-1.85%
ALLK Allakos Inc.
1.4100
+3.68%
ATYR aTyr Pharma, Inc.
3.2500
+3.17%
NKGN NKGen Biotech, Inc.
0.2700
+4.25%